Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001344627 | SCV001538692 | uncertain significance | Gorlin syndrome | 2023-04-08 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PTCH2 protein function. ClinVar contains an entry for this variant (Variation ID: 1040898). This variant has not been reported in the literature in individuals affected with PTCH2-related conditions. This variant is present in population databases (rs376282577, gnomAD 0.01%). This sequence change replaces serine, which is neutral and polar, with tyrosine, which is neutral and polar, at codon 660 of the PTCH2 protein (p.Ser660Tyr). |
Fulgent Genetics, |
RCV005014459 | SCV005650041 | uncertain significance | Basal cell carcinoma, susceptibility to, 1; Medulloblastoma | 2024-02-08 | criteria provided, single submitter | clinical testing |